Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT01578499
Registration number
NCT01578499
Ethics application status
Date submitted
27/03/2012
Date registered
17/04/2012
Date last updated
5/01/2021
Titles & IDs
Public title
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
Query!
Scientific title
A Randomized, Open-Label, Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma
Query!
Secondary ID [1]
0
0
2010-024215-14
Query!
Secondary ID [2]
0
0
C25001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ALCANZA
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Primary Cutaneous Anaplastic Large Cell Lymphoma
0
0
Query!
Mycosis Fungoides
0
0
Query!
Cutaneous T-Cell Lymphoma
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Skin
0
0
0
0
Query!
Other skin conditions
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Brentuximab Vedotin
Treatment: Drugs - Methotrexate
Treatment: Drugs - Bexarotene
Experimental: Brentuximab vedotin - Brentuximab vedotin 1.8 mg/kg, intravenous over approximately 30 minutes, once on Day 1 of each 21-day cycle and may continue as monotherapy for up to a total of 16 cycles (48 weeks).
Active Comparator: Methotrexate or Bexarotene - Methotrexate 5 to 50 mg, tablets, orally, once weekly (dose adjustment is guided by patient response and toxicity) or Bexarotene 300 mg/m^2, tablets, orally, once daily with meals for up to 48 weeks.
Treatment: Drugs: Brentuximab Vedotin
Brentuximab vedotin intravenous injection.
Treatment: Drugs: Methotrexate
Methotrexate tablets.
Treatment: Drugs: Bexarotene
Bexarotene tablets.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4)
Query!
Assessment method [1]
0
0
ORR4 was determined by an Independent Review Facility (IRF) based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic assessment by an IRF and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Participants whose first response occurred after the start of subsequent anticancer therapy were excluded. Response Criteria was based on International Society for Cutaneous Lymphomas (ISCL), United States Cutaneous Lymphoma Consortium (USCLC) and Cutaneous Lymphoma Task Force (CLTF) of the European Organisation for Research and Treatment of Cancer (EORTC) Consensus guidelines (Olsen, 2011).
Query!
Timepoint [1]
0
0
Each Cycle until disease progression, death End of treatment (Median overall follow-up 38.8 months)
Query!
Secondary outcome [1]
0
0
Percentage of Participants Achieving a CR
Query!
Assessment method [1]
0
0
Complete Response (CR) was determined by the IRF based on Global Response Score (GRS) which consisted of a skin assessment by the investigator using the modified severity-weighted assessment tool (mSWAT), nodal and visceral radiographic and for the participants with mycosis fungoides (MF) only, detection of circulation Sezary cells. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
Query!
Timepoint [1]
0
0
Each Cycle until disease progression, death or data cutoff (Median overall follow-up 38.8 months)
Query!
Secondary outcome [2]
0
0
Progression-Free Survival (PFS)
Query!
Assessment method [2]
0
0
PFS was assessed by the IRF and is defined as the time from randomization until disease progression or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
Query!
Timepoint [2]
0
0
Until disease progression, death or data cutoff (Median PFS follow-up of 38.8 months)
Query!
Secondary outcome [3]
0
0
Maximum Change From Baseline in Symptom Domain Score of the Skindex-29 Questionnaire
Query!
Assessment method [3]
0
0
Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, from 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement.
Query!
Timepoint [3]
0
0
Baseline up to End of Treatment (Week 52)
Query!
Secondary outcome [4]
0
0
Duration of Response (DOR)
Query!
Assessment method [4]
0
0
Duration of response was assessed by the IRF in participants with confirmed response [CR or Partial Response (PR)] and is defined as the time between first documentation of response and disease progression. Response Criteria was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
Query!
Timepoint [4]
0
0
Until disease progression, death or data cutoff (Median follow-up 38.8 months)
Query!
Secondary outcome [5]
0
0
DOR of Skin Response
Query!
Assessment method [5]
0
0
Duration of skin response (CR and PR) was assessed by the investigator and is defined as the time between the first skin response to progressive disease in skin. Per mSWAT, CR is defined as 100% clearance of skin lesions. PR is defined as 50%-99% clearance of skin disease from Baseline; No new tumors in participants without tumors at Baseline -MF; No new tumors-primary cutaneous anaplastic large cell lymphoma (pcALCL).Progressive disease is defined as = 25% increase in skin disease from baseline, or loss of response: in those with CR or PR, increase of skin score of greater than the sum of nadir plus 50% baseline score, or new tumors in participants without tumors at baseline (MF).
Query!
Timepoint [5]
0
0
Until disease progression, death or data cutoff (Median follow-up 38.8 months)
Query!
Secondary outcome [6]
0
0
Event-Free Survival (EFS)
Query!
Assessment method [6]
0
0
EFS was assessed by the IRF and is defined as the time from randomization until any cause of treatment failure: disease progression, discontinuation of treatment for any reason, or death due to any cause, whichever occurs first. Disease progression was based on ISCL, USCLC and CLTF of the EORTC Consensus guidelines (Olsen, 2011).
Query!
Timepoint [6]
0
0
From randomization until disease progression, death or data cutoff (Median follow-up 36.8 months)
Query!
Secondary outcome [7]
0
0
Cmax: Maximum Observed Concentration for Brentuximab Vedotin
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
Day 1 pre-dose and 30 minutes after infusion in Cycles 1 and 3
Query!
Secondary outcome [8]
0
0
Ctrough: Observed Concentration at the End of a Dosing Interval for Brentuximab Vedotin
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
Day 1 pre-dose of Cycles 2 and 4
Query!
Secondary outcome [9]
0
0
Cmax: Maximum Observed Concentration for Monomethyl Auristatin (MMAE) for Brentuximab Vedotin
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
Day 1 pre-dose and 30 minutes after infusion ended in Cycles 1 and 3
Query!
Secondary outcome [10]
0
0
Ctrough: Observed Concentration at the End of a Dosing Interval for MMAE for Brentuximab Vedotin
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
Day 1 pre-dose of Cycles 2 and 4
Query!
Secondary outcome [11]
0
0
Number of Participants With Antitherapeutic Antibodies (ATA) to Brentuximab Vedotin
Query!
Assessment method [11]
0
0
Blood was collected and evaluated for ATA and neutralizing ATA in all participants who received brentuximab vedotin to assess immunogenicity.
Query!
Timepoint [11]
0
0
Baseline up to End of Treatment (Week 52)
Query!
Secondary outcome [12]
0
0
Change From Baseline in the Skindex-29 Questionnaire Total Score
Query!
Assessment method [12]
0
0
Skindex-29 is a 29-item dermatology-specific health-related quality of life (HRQoL). The Skindex-29 incorporates a 28-day recall period and consists of 3 domains: symptoms, emotions, and functioning. The domain scores and an overall score are expressed on a 100-point scale, 0 to 100 with higher scores indicating lower levels of health- HRQoL. A negative change (reduction) from Baseline indicates improvement.
Query!
Timepoint [12]
0
0
Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at End of Treatment (EOT) and during posttreatment long treatment follow-up (LTFU) - (Median follow-up 38.8 months)
Query!
Secondary outcome [13]
0
0
Change From Baseline in Functional Assessment of Cancer Therapy General Questionnaire (FACT-G) Score
Query!
Assessment method [13]
0
0
FACT-G is a 27-item general cancer QOL instrument completed by participants receiving cancer treatment. FACT-G incorporates a 7-day recall period and contains 4 primary subscales: Physical Well-Being (PWB; sum of 7 items, point range 0-28); Social/Family Well-Being (SWB, sum of 7-items, point range 0-28); Emotional Well-Being (EWB; sum of 6-items, point range 0-24); Functional Well-Being (FWB; sum of 7-items, point range 0-28); Fact-G total score=sum of PWB, SWB, EWB, FWB, point range 0-108. Higher scores for the total scales and subscales indicate better quality of life. A negative change (reduction) from Baseline indicates improvement.
Query!
Timepoint [13]
0
0
Day 1 of Cycles 1, 2, 4, 6, 8, 10, 12, 14, 16, at EOT and during posttreatment (LTFU) - (Median follow-up 38.8 months)
Query!
Secondary outcome [14]
0
0
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [14]
0
0
AEs and SAEs were assessed according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03. An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A SAE is any AE that results in death, is life-threatening, requires inpatient hospitalization or prolongation of an existing hospitalization, results in significant disability or incapacity, is a congenital anomaly/birth defect or is a medically important event.
Query!
Timepoint [14]
0
0
First dose of study drug through 30 days after last dose of study drug (Up to 450 days)
Query!
Eligibility
Key inclusion criteria
- Voluntary consent form
- Male or female participants 18 years or older with diagnosis of mycosis fungoides (MF)
or primary cutaneous anaplastic large cell lymphoma (pcALCL)
- Participants with pcALCL who have received prior radiation therapy or at least 1 prior
systemic therapy; participants with MF who have received at least 1 prior systemic
therapy
- Histologically confirmed CD30+ disease by central laboratory assessment and pathology
review
- Eastern Cooperative Oncology Group (ECOG) performance status = 2
- Female participants who are post menopausal, surgically sterile, or agree to practice
2 effective methods of contraception or agree to practice true abstinence, when this
is in line with the preferred and usual lifestyle of the participant
- Male participants who agree to practice effective barrier contraception or agree to
practice true abstinence, when this is in line with the preferred and usual lifestyle
of the participant
- Clinical laboratory values as specified in protocol
- A 3-week washout period is required from previous treatments (with the exception of a
12-week washout for antibody-directed or immunoglobulin-based immune therapy, or other
monoclonal antibody therapies), unless it is not in the best interest of the patient
in the opinion of the investigator. Individual cases should be discussed with the
project clinician before enrollment.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- A concurrent diagnosis of systemic ALCL, or other non Hodgkin lymphoma (excluding LyP)
or Sezary syndrome or B2 disease
- Participants with cardiovascular conditions specified in protocols
- Participants with history of another primary malignancy not in remission for at least
3 years
- Known active cerebral/meningeal disease, including signs or symptoms of progressive
multifocal leukoencephalopathy (PML);
- Known human immunodeficiency virus (HIV) infection, hepatitis B or Hepatitis C
infection
- Oral retinoid therapy for any indication within 3 weeks of study entry
- Corticosteroid therapy within 3 weeks or immunosuppressive chemotherapy or any
antibody-directed or immunoglobulin-based immune therapy (e.g., immunoglobulin
replacement, other monoclonal antibody therapies) within 12 weeks of first dose of
study drug
- Female participants who are lactating and breastfeeding or have a positive serum
pregnancy test during the screening period or a positive urine pregnancy test on Day 1
of any cycle
- Previous receipt of brentuximab vedotin Please note that there are additional
inclusion and exclusion criteria. The study center will determine if you meet all of
the criteria.
Site personnel will explain the trial in detail and answer any question you may have if you
do qualify for the study. You can then decide whether or not you wish to participate. If
you do not qualify for the trial, site personnel will explain the reasons.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
11/06/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
6/07/2018
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
131
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA
Query!
Recruitment hospital [1]
0
0
- Concord
Query!
Recruitment hospital [2]
0
0
- South Brisbane
Query!
Recruitment hospital [3]
0
0
- Adelaide
Query!
Recruitment hospital [4]
0
0
- Nedlands
Query!
Recruitment hospital [5]
0
0
- East Melbourne
Query!
Recruitment postcode(s) [1]
0
0
- Concord
Query!
Recruitment postcode(s) [2]
0
0
- South Brisbane
Query!
Recruitment postcode(s) [3]
0
0
- Adelaide
Query!
Recruitment postcode(s) [4]
0
0
- Nedlands
Query!
Recruitment postcode(s) [5]
0
0
- East Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
California
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Illinois
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Massachusetts
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
New Jersey
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
New York
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Pennsylvania
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Texas
Query!
Country [8]
0
0
Austria
Query!
State/province [8]
0
0
St. Poelten
Query!
Country [9]
0
0
Austria
Query!
State/province [9]
0
0
Wien
Query!
Country [10]
0
0
Belgium
Query!
State/province [10]
0
0
Leuven
Query!
Country [11]
0
0
Brazil
Query!
State/province [11]
0
0
Sao Paulo
Query!
Country [12]
0
0
France
Query!
State/province [12]
0
0
Nantes Cedex 01
Query!
Country [13]
0
0
France
Query!
State/province [13]
0
0
Paris
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Pessac Cedex
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Pierre Benite
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Reims
Query!
Country [17]
0
0
Germany
Query!
State/province [17]
0
0
Kiel
Query!
Country [18]
0
0
Germany
Query!
State/province [18]
0
0
Krefeld
Query!
Country [19]
0
0
Germany
Query!
State/province [19]
0
0
Mainz
Query!
Country [20]
0
0
Germany
Query!
State/province [20]
0
0
Mannheim
Query!
Country [21]
0
0
Germany
Query!
State/province [21]
0
0
Minden
Query!
Country [22]
0
0
Germany
Query!
State/province [22]
0
0
Wurzburg
Query!
Country [23]
0
0
Italy
Query!
State/province [23]
0
0
Bologna
Query!
Country [24]
0
0
Italy
Query!
State/province [24]
0
0
Firenze
Query!
Country [25]
0
0
Italy
Query!
State/province [25]
0
0
Meldola
Query!
Country [26]
0
0
Poland
Query!
State/province [26]
0
0
Warszawa
Query!
Country [27]
0
0
Spain
Query!
State/province [27]
0
0
Navarra
Query!
Country [28]
0
0
Spain
Query!
State/province [28]
0
0
Barcelona
Query!
Country [29]
0
0
Spain
Query!
State/province [29]
0
0
Madrid
Query!
Country [30]
0
0
Switzerland
Query!
State/province [30]
0
0
Zurich
Query!
Country [31]
0
0
United Kingdom
Query!
State/province [31]
0
0
West Yorkshire
Query!
Country [32]
0
0
United Kingdom
Query!
State/province [32]
0
0
Birmingham
Query!
Country [33]
0
0
United Kingdom
Query!
State/province [33]
0
0
Glasgow
Query!
Country [34]
0
0
United Kingdom
Query!
State/province [34]
0
0
London
Query!
Country [35]
0
0
United Kingdom
Query!
State/province [35]
0
0
Manchester
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Millennium Pharmaceuticals, Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/Industry
Query!
Name [1]
0
0
Seagen Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The purpose of this study is to determine objective response rate (ORR), lasting at least 4
months (ORR4), with brentuximab vedotin in participants with cluster of differentiation
antigen 30 positive (CD30+) cutaneous T-cell lymphoma [mycosis fungoides (MF) and primary
cutaneous anaplastic large cell lymphoma (pcALCL) ]compared to that achieved with therapy in
the control arm.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT01578499
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Medical Monitor
Query!
Address
0
0
Millennium Pharmaceuticals, Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT01578499
Download to PDF